Mirae Asset Global Investments Co. Ltd. Buys 29,825 Shares of Quest Diagnostics Incorporated $DGX

Posted by Stanley Muller on Nov 6th, 2026

Mirae Asset Global Investments Co. Ltd. bought a new position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 29,825 shares of the medical research company’s stock, valued at approximately $6,951,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Quest Diagnostics during the 2nd quarter worth about $1,965,923,000. EdgePoint Investment Group Inc. increased its holdings in shares of Quest Diagnostics by 35.1% in the first quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock valued at $439,753,000 after purchasing an additional 582,797 shares during the period. Bank of America Corp DE acquired a new position in shares of Quest Diagnostics in the second quarter valued at about $410,151,000. Dimensional Fund Advisors LP raised its stake in shares of Quest Diagnostics by 0.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,949,535 shares of the medical research company’s stock worth $382,085,000 after purchasing an additional 17,987 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Quest Diagnostics by 11.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 942,407 shares of the medical research company’s stock worth $199,743,000 after purchasing an additional 95,804 shares during the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Trading Down 0.5%

NYSE DGX opened at $254.53 on Friday. Quest Diagnostics Incorporated has a 1 year low of $171.18 and a 1 year high of $259.00. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.70 and a quick ratio of 1.58. The company has a market capitalization of $28.00 billion, a PE ratio of 23.16, a P/E/G ratio of 2.29 and a beta of 0.55. The company has a fifty day moving average of $239.12 and a 200 day moving average of $213.35.

Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its quarterly earnings results on Thursday, October 22nd. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.87 by $0.13. The company had revenue of $3.10 billion for the quarter, compared to the consensus estimate of $3.05 billion. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period last year, the firm earned $2.60 EPS. Research analysts forecast that Quest Diagnostics Incorporated will post 11.29 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th were issued a $0.86 dividend. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend was Tuesday, October 6th. Quest Diagnostics’s payout ratio is 34.26%.

Insider Buying and Selling

In related news, Director Gary M. Pfeiffer sold 1,203 shares of the firm’s stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $243.00, for a total transaction of $292,329.00. Following the sale, the director directly owned 29,802 shares of the company’s stock, valued at $7,241,886. This trade represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Catherine T. Doherty sold 22,105 shares of Quest Diagnostics stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $248.02, for a total value of $5,482,482.10. Following the transaction, the executive vice president owned 71,949 shares of the company’s stock, valued at approximately $17,844,790.98. This represents a 23.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 55,985 shares of company stock worth $13,715,017 over the last ninety days. 0.88% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on DGX shares. UBS Group reaffirmed a “neutral” rating and set a $250.00 target price on shares of Quest Diagnostics in a report on Monday, October 19th. Truist Financial upped their target price on Quest Diagnostics from $250.00 to $260.00 and gave the company a “hold” rating in a research report on Monday, September 21st. Wall Street Zen upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday, July 28th. Argus set a $260.00 price target on shares of Quest Diagnostics in a research report on Wednesday, July 29th. Finally, Mizuho raised their price target on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $248.70.

Get Our Latest Report on Quest Diagnostics

About Quest Diagnostics

(Free Report)

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.